Why Perspective Therapeutics, Inc.’s (CATX) Stock Is Up 5.97%
As of Friday, November 13, Perspective Therapeutics, Inc.’s CATX share price has surged by 5.97%, which has investors questioning if this is right time to sell.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Tudor Pop
Tudor Pop
Rosalio Madrigal
| Share Statistics | CATX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $111.6 | $202.9 | 24% |
|
| Shares Out (Mil) | 120.7 | 55.4 | 65% |
|
| Institutional Ownership | 98.8% | 92.9% | 81% |
|
| Float (Mil) | 81.3 | 40.7 | 56% |
|
| Beta | 1.99 | 1.04 | 92% |
|
| Avg Daily Volume (000s) | 5,001 | 566 | 91% |
|
| Price Change (52-week) |
(55.4%) | 41.0% | 18% |
|
| Growth | CATX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (38.3%) | 13.2% | 1% |
|
| Net Income (5yr) | (97.9%) | (10.3%) | 2% |
|
| EPS (5yr) | (33.8%) | 15.8% | 7 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (15.7%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 8 | na | |
| Current EPS | ($0.261) | ($0.968) | na | |
| Month Ago EPS | ($0.261) | ($0.992) | na | |
| # Rev Up | 1 | 2 | na | |
| # Rev Down | 1 | 0 | na | |
| Three Months Ago EPS | ($0.265) | ($1.035) | na | |
| Year/Year Chg | (3.0%) | (31.1%) | (26.6%) | |
| Financials | CATX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $39 | 0% |
|
| Net Income (TTM) (Mil) | ($123) | ($44) | 9% |
|
| EPS (TTM) | ($1.172) | ($1.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($108) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $14 | ($1) | 61% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | ($103) | $144 | 0% |
|
| Valuation | CATX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.36 | 1.97 | 8% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | CATX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (37.2%) | (47.4%) | 14% |
|
| ROE | (45.8%) | (53.5%) | 16% |
|
| Liabilities to Assets | 19.4% | 29.7% | 12% |
|
| F-Score | 1 | 3 | na |
|
Perspective Therapeutics, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors